Prof. Alfredo Addeo is a consultant medical oncologist, head of the Oncology Service, and leading lung physician within the Department of Oncology at the University Hospital of Geneva (HUG), Switzerland.
His primary research interests lie in predictive and prognostic biomarkers and
patient-reported outcomes in thoracic malignancies. Throughout his career, he has authored numerous publications in several international peer-reviewed journals. Many of Prof. Addeo’s works within the field of non-small cell lung cancer (NSCLC) focus on immunotherapies, including immune checkpoint inhibitors, and oncogenic biomarkers such as EGFR, HER2, and PD-L1.
In addition, Prof. Addeo has led numerous translational research projects focused on tumour development and targeted therapies. He is an active member of the European Society for Medical Oncology (ESMO), the European Thoracic Oncology Platform (ETOP), and the International Association for the Study of Lung Cancer (IASLC).
